NCT02225106View on ClinicalTrials.gov

Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 6, 2014

Primary Completion Date

June 21, 2017

Study Completion Date

June 21, 2017

Conditions
Cognition DisorderAttention Deficit DisorderTraumatic Brain Injury
Interventions
DRUG

Methylphenidate

Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

University of Pennsylvania

OTHER

NCT02225106 - Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI | Biotech Hunter | Biotech Hunter